Related Experiment Video
Updated: Aug 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides
1The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia. p.barter@hri.org.au
Abstract:
Treatment with statins reduces coronary risk In all people but do not remove the risk associated with a low HDL-C or with other features of the metabolic syndrome such as an elevated level of plasma triglyceride or with a high BMI. Treatment with a fibrate such as gemfibrozil (a PPAR alpha agonist) has been shown to be especially effective in people with low HDL-C and other features of the metabolic syndrome. Potential beneficial effects of the combination of a statin and an agent with PPAR alpha activity in patients with type 2 diabetes is currently being addressed in the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease IV: Preventive Measures
Angina IV: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...